Identification of Biomarkers, New Treatments, and Vaccines for COVID-19

The novel coronavirus 2019 (COVID-19) has caused a serious global pandemic in just one year. Nearly every country and territory in the world has been affected by the virus. The virulence and infection rate of the virus are profound, and has required extreme social distancing measures across the globe in order to prevent overwhelming the healthcare services and hospitals. COVID-19 appears to have the greatest effects on elderly individuals and those who have co-morbid diseases, such as diabetes and obesity. As the cases and death rate remain high, there are justified fears of this virus remaining for several months or years to come. To address this, a rapid and unprecedented worldwide mobilization effort has begun to identify effective treatments and develop vaccines. As these begin to be deployed and administered across the globe, many now feel the virus will be brought under control and lives will eventually return to normal.

Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 38 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and age-related diseases such as diabetes, cancer, cardiovascular disorders, sarcopenia and Alzheimer's disease.